Ben Gilbert: belief

Transcript context

…Regardless, the next year 2015 is a record year, total company revenues for Novo Nordisk hit $16 billion, which is incredible for a pure play Diabetes and now Diabetes and relatedly obesity pharma company, but the stock flatlines. Yeah. Right around the same time, you've got the Insulin pricing scandal, where America is waking up to the idea that Insulin is getting more and more expensive, and it's becoming more and more essential for a huge population of people. This is across the whole industry. It's Sanofi, it's Novo Nordisk, and it's Eli Lilly. Everyone's Insulin has gotten more expensive, and they come under fire in the public eye, the Saxenda not being the blockbuster drug that expectations had trumpeted it up to be, plus this increasing pressure around Insulin, and I think a CEO change. Yeah. The CEO change, I think, was a result of this. What you're leading up to is in 2016, the stock takes a 40% hit, which is wild. Today at the beginning of 2024, this is a half a trillion dollar company. A few years ago, it was a well less than a hundred billion dollar market cap company.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.